July 31, 2023
Company Name: AnGes Inc.
Presentative: Ei Yamada, President & CEO

Notice Concerning the Conclusion of an Agreement with the Gunma Health
Promotion Foundation for Extended Newborn Screening in Gunma Prefecture

AnGes, Inc. announces that it has entered into an agreement with the Gunma Foundation for
Health Promotion (“Health Promotion Foundation”) for AnGes Clinical Research Laboratory (“ACRL”),
a health laboratory mainly for testing for rare genetic diseases, to start contracted expanded newborn
screening testing from August 1, 2024.
ACRL has recently signed an agreement with the Foundation for Health Promotion to contractwith the Health Promotion Foundation for an expanded newborn screening test for seven rare genetic
diseases*1 for which early diagnosis and early treatment are extremely effective, for a fee to those whowish to take the test.
Health Promotion Foundation is in charge of newborn screening at medical institutions in Gunma
Prefecture, and with the conclusion of this contract, newborns born at medical institutions in Gunma
Prefecture will be able to receive, for a fee, not only the examination for congenital metabolic
abnormalities (newborn mass screening), which is provided to all newborns at public expense, but also
examinations for 7 diseases not included in the above.
In line with our corporate philosophy of “contributing to the realization of healthy and hopefullifestyles through the development and commercialization of innovative genetic medicines for diseases
for which there is no cure, intractable diseases, and rare diseases,” we will continue to strive for asociety in which as many people as possible can benefit from early detection and early treatment ofrare diseases through this testing business.
Since the revenue from the inspection business resulting from the conclusion of this agreement
is included in the consolidated earnings forecast for the current fiscal year announced on March 14,2024, the earnings forecast remains unchanged.
About ACRL
ACRL has been contracted by the Association for the Advancement of Rare Diseases in Medicine andResearch (hereinafter referred to as “CReARID ‘*2) since April 1, 2021 to perform ’optional screening,” anexpanded newborn screening test, with approximately 10,000 tests per year in 2022 and 20,000 tests per year
in 2023. The laboratory is the largest laboratory in Japan.
In addition to being able to perform expanded newborn screening tests for nine diseases, the largest
number of test items in Japan, the laboratory has established a system *3 that allows it to accept tests for only
some of the nine diseases in the expanded newborn screening tests, in response to requests from local
governments and other organizations.
(Note)This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.

*1 Seven target diseases: Mucopolysaccharidosis type I, II, IVA, VI, Fabry disease (boys only), Pompe disease,
Adrenoleukodystrophy (ALD: boys only)*2 CReARID uses the latest testing technology to help detect rare genetic disorders at an early stage or before
they develop, connecting physicians and specialists who struggle to diagnose rare genetic disorders andsupporting early diagnosis and appropriate treatment options.
http://www.crearid.or.jp/*3 Expanded newborn screening contract at ACRL
Local
# ofFabry Pompe MPS1
Goverment diseases

MOS2 MPS4A MPS6

PID/SCIDSMAALD

A

9ACRL

ACRL

ACRL

ACRLACRL

ACRL

ACRL

ACRL

ACRL

B

7

ACRL

ACRL

ACRL

ACRL

ACRL

ACRL

Labo1

Labo1

ACRL

C4

ACRL

ACRL

ACRL

ACRL－－Labo2

Labo2－(Note)This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.